<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111809</url>
  </required_header>
  <id_info>
    <org_study_id>APH190198</org_study_id>
    <nct_id>NCT04111809</nct_id>
  </id_info>
  <brief_title>Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care</brief_title>
  <acronym>AMBROBiMM</acronym>
  <official_title>Assessment of 4 Bone Turnover Markers (C-terminal Telopeptides of Type I Collagene (CTX), Amino-terminal Telopeptide of Type 1 Collagen (NTX), Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in Multiple Myeloma Patients Treated With Intravenous Bisphosphonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intergroupe Francophone du Myelome</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is looking at the Kinetics of bone turnover markers (C-terminal
      telopeptides of type I collagene (CTX), amino-terminal telopeptide of type 1 collagen (NTX),
      Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in serum and urine until 12 months in Patients with
      Multiple Myeloma Treated With intravenous bisphosphonates in routine care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in bone turnover markers</measure>
    <time_frame>Baseline, then every 2 months in 12 months</time_frame>
    <description>bone turnover markers include: C-terminal telopeptides of type I collagene (CTX) in serum, amino-terminal telopeptide of type 1 collagen (NTX) in urine, Dickkopf-1 (DKK-1) and Sclerostin (SOST) in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to maximum variation of bone turnover markers</measure>
    <time_frame>Baseline, then every 2 months in 12 months</time_frame>
    <description>CTX, NTX, DKK-1 and SOST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of intravenous bisphosphonate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To study the relationship between doses and bone turnover markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intravenous bisphosphonate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To study the relationship between doses and bone turnover markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of bone lesions by imaging</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>evolution of bone lesions by imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new bone events</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events likely to be related to bisphosphonate</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Monoclonal protein</measure>
    <time_frame>Baseline, then every 2 months in 12 months</time_frame>
    <description>To evaluated response to treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>intravenous biphosphonate</arm_group_label>
    <description>Patients treated with intravenous bisphosphonate until 12 months in routine care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood and urine collection</intervention_name>
    <description>collected 10 mL of blood and 15 mL of urine every 2 months until 12 months</description>
    <arm_group_label>intravenous biphosphonate</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum plasma urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        no description
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient aged 65 to 75 years of age

          2. Patient with symptomatic multiple myeloma as defined by the criteria of the IMWG

          3. Need to introduced an antiresorptive bone treatment by intravenous bisphosphonate with
             bone imaging mapping (PET-scanner preferentially) in routine care

          4. Ability and willingness to follow scheduled visits with requested biological samples

        Exclusion Criteria

        - Patients previously treated with intravenous biphosphonate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurent Frenzel, MD</last_name>
    <phone>+33 (0)1 44 49 52 90</phone>
    <email>laurent.frenzel@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie JOLAINE</last_name>
    <phone>: +33 1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>intravenous bisphosphonate</keyword>
  <keyword>bone markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

